GENTIBIO
Live / Applied — First extension granted (statement of use) (as of 22 Oct 2025)
What this means for you
Not registered yet, but its 01 Apr 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98478168
- Mark type
- Stylized text
- Filed
- 01 Apr 2024
- Published for opposition
- 25 Feb 2025
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders, allergic diseases and disorders, autoimmune diseases and disorders, acute illness, diabetes, stroke, inflammation and inflammatory disease, respiratory and infectious diseases, acute respiratory distress illness, immunological disorders and metabolic diseases; Autologous therapies, namely, cells for medical purposes; Allogeneic therapies, namely, cells for medical purposes; Biological preparations for the treatment of cancer, namely, virotherapies; Human cells for medical purposes; Cells for medical therapy use; Cultured human cells for medical therapeutic use
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals and therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases, for others; Custom manufacturing of biological cells; Consultation in the field of custom manufacture of pharmaceuticals, therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases and biological cells
- Class 042 — Scientific and technological services: Scientific research; Pharmaceutical and medical therapeutic research services; Medical research; Engineering of biological cells; Genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering
Owner
- GentiBio, Inc., Cambridge, MA, US
- GentiBio, Inc., Cambridge, MA, US
Prosecution history
- 23 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Oct 2025 — SOU EXTENSION 1 GRANTED
- 22 Oct 2025 — SOU EXTENSION 1 FILED
- 22 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Feb 2025 — PUBLISHED FOR OPPOSITION
- 19 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 06 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 06 Jan 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Oct 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Oct 2024 — NON-FINAL ACTION E-MAILED
- 19 Oct 2024 — NON-FINAL ACTION WRITTEN